Talis Biomedical Corporation - common stock (TLIS)
4.3800
+0.00 (0.00%)
Talis Biomedical Corp is a biotechnology company focused on developing innovative diagnostic solutions for infectious diseases
The company aims to enhance the speed and accuracy of pathogen detection through its proprietary technology platform, which integrates molecular diagnostics with advanced automation. By creating devices that can deliver rapid test results, Talis seeks to improve patient care and facilitate timely decision-making in clinical environments, particularly in the context of critical conditions where early diagnosis is essential.
NEW YORK, April 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Talis Biomedical Corporation Talis Biomedical Corporation (NASDAQ: TLIS), TaskUs, Inc. (NASDAQ: TASK), and Rent the Runway, Inc. (NASDAQ: RENT) on behalf of long-term stockholders. More information about each potential case can be found at the link provided.
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Talis Biomedical Corporation (NASDAQ: TLIS) on behalf of long-term stockholders following a class action complaint that was filed against Talis on March 8, 2022 with a Class Period relating to stock purchases made pursuant to the Company’s February 2021 IPO. Our investigation concerns whether the board of directors of Talis have breached their fiduciary duties to the company.
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Talis Biomedical Corporation (NASDAQ: TLIS) on behalf of long-term stockholders following a class action complaint that was filed against Talis on March 8, 2022 with a Class Period relating to stock purchases made pursuant to the Company’s February 2021 IPO. Our investigation concerns whether the board of directors of Talis have breached their fiduciary duties to the company.
REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions.
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023.
Preliminary data suggest a chlamydia, gonorrhea and trichomonas (CT/NG/TV) multiplex test is feasible on a molecular point-of-care (POC) test system with time to result in less than 30 minutes
REDWOOD CITY, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated July 20, 2023, that the Company has regained compliance with the minimum bid price requirement of at least $1.00 per share under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In order to regain compliance, the Company’s common stock was required to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days which the Company satisfied on July 19, 2023. Accordingly, the Notice stated that Nasdaq now considers the matter closed.
REDWOOD CITY, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will effect a 1-for-15 reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share (the “Reverse Stock Split”), effective at 5:00 p.m. Eastern time on July 5, 2023 (the “Effective Time”). The Company’s common stock will begin trading on a reverse stock split adjusted basis on The Nasdaq Capital Market at market open on July 6, 2023.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Talis Biomedical Corporation (NASDAQ: TLIS) on behalf of long-term stockholders following a class action complaint that was filed against Talis on March 8, 2022 with a Class Period relating to stock purchases made pursuant to the Company’s February 2021 IPO. Our investigation concerns whether the board of directors of Talis have breached their fiduciary duties to the company.
REDWOOD CITY, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced Heiner Dreismann has joined its board of directors, effective immediately. Talis Bio also recently appointed Kim Popovits, who has served as a member of the board since March 2020, as its lead independent director.
REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will provide a business update and financial results on Thursday, May 11, 2023, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Shareholder rights law firm Robbins LLP is investigating Talis Biomedical Corporation (NASDAQ: TLIS) to determine whether certain Talis officers and directors violated securities laws and breached fiduciary duties to shareholders in connection with the Company’s February 2021 initial public offering ("IPO"). Talis purportedly develops diagnostic tests for infectious diseases and other conditions at the point-of-care. The Talis One tests are being developed for respiratory infections, infections related to women's health, and sexually transmitted infections.
REDWOOD CITY, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the fourth quarter and full year ended December 31, 2022.
REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the third quarter ended September 30, 2022.
San Diego, CA -- (SBWIRE) -- 05/10/2022 -- Certain directors of Talis Biomedical Corporation are under investigation over potential breaches of fiduciary duties.
Los Angeles - (NewMediaWire) - March 08, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Talis Biomedical Corporation (“Talis” or “the Company”) (NASDAQ: TLIS) for violations of the federal securities laws.
WHY: NEW YORK, NY - (NewMediaWire) - March 8, 2022 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Talis Biomedical Corporation (NASDAQ: TLIS) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s February 2021 initial public offering (“IPO” or the “Offering”), of the important March 8, 2022 lead plaintiff deadline.
Los Angeles - (NewMediaWire) - March 07, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Talis Biomedical Corporation (“Talis” or “the Company”) (NASDAQ: TLIS) for violations of the federal securities laws.
San Diego, CA -- (SBWIRE) -- 03/07/2022 -- The Shareholders Foundation announced that a deadline is coming up on March 8, 2021 in the lawsuit filed for certain investors of Talis Biomedical Corporation (NASDAQ:TLIS)
